Teladoc Q2 Miss Signals Near-Term Pressure as Revenue Guidance Drops
Missed revenue and reduced full-year guidance combined with a sizable after-hours drop indicate meaningful near-term downside risk.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Missed revenue and reduced full-year guidance combined with a sizable after-hours drop indicate meaningful near-term downside risk.
What happened, with direct paths to the underlying reporting
Teladoc posted Q2 revenue of $606.9 million, down 4% YoY and below consensus. Integrated Care rose modestly while BetterHelp declined, with US revenue down and cash-pay pressure mounting. The company cut full-year revenue guidance and issued a broader loss outlook, though Teladoc One launches could offer a longer-term upside, the near-term setup remains challenging.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.